Nitrofurantoin Synchrony Pharma (Nitrofurantoin)

Nitrofurantoin is reduced by bacterial enzymes to reactive metabolites that damage bacterial DNA, RNA and protein synthesis pathways. By inhibiting key enzymes in carbohydrate metabolism, it exerts a bactericidal effect against common urinary pathogens, particularly Gram‑negative organisms such as Escherichia coli.

The dosage of Nitrofurantoin Synchrony Pharma is determined by the prescribing clinician based on the patient’s infection severity, renal function and other clinical factors. Healthcare professionals set the appropriate strength, frequency and duration of therapy according to current medical guidelines.

Nitrofurantoin is classified as pregnancy category B, indicating no evidence of fetal risk in animal studies, but it should be avoided near term because of potential neonatal hemolysis. It is excreted in breast milk in small amounts; breastfeeding mothers should discuss risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other urinary antiseptics such as trimethoprim‑sulfamethoxazole, nitrofurantoin offers a narrow spectrum focused on common uropathogens and retains activity against many resistant strains. It is not absorbed systemically in high amounts, reducing the risk of systemic side effects, but it requires adequate renal function for effective urinary concentrations.

Nitrofurantoin Synchrony Pharma should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

The medication is taken orally, usually with food or a full glass of water to minimize gastrointestinal irritation. Patients should swallow the tablets whole and follow the dosing schedule prescribed by their healthcare professional, completing the full course even if symptoms improve.

Serious adverse reactions include pulmonary toxicity (which can be acute or chronic), hepatic injury, and hemolytic anemia in individuals with glucose‑6‑phosphate dehydrogenase deficiency. Patients should seek immediate medical attention if they develop persistent cough, shortness of breath, jaundice, dark urine, or unexplained fatigue.

Nitrofurantoin is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to nitrofurantoin or other nitrofurans, and those with glucose‑6‑phosphate dehydrogenase deficiency due to the risk of hemolysis. Caution is also advised in late pregnancy and in patients with a history of pulmonary disease.